Figure 7
Avocatin B SEDDS show bioavailability and biodistribution in a pilot in vivo pharmacokinetic study. Avocatin B SEDDS (2% w/w) was delivered via gavage (100 mg/kg body weight (b.w.)) to 6–8 week old female C57BL/6J mice. (A) 50–100 µL blood was collected via tail-snips at 2 hr, 6 hr and endpoint (24 hr). Avocadene and avocadyne were quantified in blood using a validated LC-MS bio-analytical method. (B) Tissues (bone marrow, heart, pancreas, liver, gonadal fat pad, inguinal fat pad, and brain) were collected at endpoint for avocadene and avocadyne quantification. Data are shown as mean ± S.D., N = 3 in each group.
